arrow
D

Duncan Bellamy

Jenner Institute
H指数:21
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings

B和T细胞对流行病学设置中红细胞前期R21/Matrix-M和红细胞期RH5.1/Matrix-M疟疾疫苗的应答

2026-03-040
OA
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E
2025-02-060
OAAI
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
2024-05-016
OAAI
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

布基纳法索儿童R21/Matrix-M疫苗对临床疟疾的疗效和免疫原性: 1/2b期随机对照试验

2022-12-01142
OAAI
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria
2022-02-0713
OAAI
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
2021-07-3035
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (vol 27, pg 270, 2021)
2021-05-215
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021)
2021-05-066
OAAI
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

布基纳法索儿童季节性接种低剂量候选疟疾疫苗R21和佐剂matrix-m的疗效: 一项随机对照试验

LANCET
IF88.5
2021-05-01270
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020-12-17454
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020-12-17233
OAAI
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

ChAdOx1 nCoV-19疫苗抗SARS-CoV-2的安全性和免疫原性: 1/2期单盲随机对照试验的初步报告

LANCET
IF88.5
2020-08-011.7K
OAAI
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
2020-07-01166
OAAI